x POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

See other indications for POMALYST:

This website is intended for U.S. Healthcare Professionals.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

Safety profile of POMALYST® (pomalidomide) + dex + daratumumab (DPd).1

Full Adverse Reactions Table

aInfusion reaction includes terms determined by investigators to be related to infusion. Severe infusion reactions included bronchospasm, dyspnea, laryngeal edema, pulmonary edema, hypoxia, and hypertension.

Other adverse infusion reactions were nasal congestion, cough, chills, throat irritation, vomiting, and nausea.

bAcute tonsillitis, bronchitis, laryngitis, nasopharyngitis, pharyngitis, respiratory syncytial virus infection, rhinitis, sinusitis, tonsillitis, upper-respiratory tract infection.

cCough, productive cough, allergic cough.

dDyspnea, dyspnea exertional.

13% of patients discontinued treatment due to adverse reaction(s).1

  • Median treatment duration: 6 months (range: 0.03-16.9 months)
  • Neutropenia (95%) was the most commonly reported adverse reaction
    • 44% of patients presented with Grade 1 or 2 neutropenia at baseline2
  • The overall incidence of serious adverse reactions was 49%
    • Serious adverse reactions reported in ≥5% of patients included pneumonia (7%)

Information about DPd does not appear in the POMALYST full Prescribing Information. Please see the daratumumab full Prescribing Information for a discussion of Important Safety Information at

dara, daratumumab; dex, dexamethasone; DPd, POMALYST + dexamethasone + daratumumab; IV, intravenous.

References: 1. Daratumumab [package insert]. Horsham, PA: Janssen Biotech, Inc. 2. Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130(8):974-981. 3. POMALYST [package insert]. Summit, NJ: Celgene Corp.

Learn more about POMALYST once-daily
oral dosing and dose modifications.3

See Dose Modifications